BridgeBio Pharma Inc (NASDAQ:BBIO) at last check was buoying at $45.15 on current market day with a rise of 0.07% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $45.12 and 5Y monthly beta was reading 1.1 with its price kept floating in the range of $44.89 and $45.41 on the day. Considering stock’s 52-week price range provides that BBIO hit a high price of $45.18 and saw its price falling to a low level of $21.72 during that period. Over a period of past 1-month, stock came adding 39.96% in its value.
In contrast, when we review BBIO stock’s current outlook then short term indicators are assigning it an average of 100% Buy, while medium term indicators are categorizing the stock at an average of 100% Buy. Long term indicators are suggesting an average of 100% Buy for it.
According to ratings assigned by 9 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 0 of them are recommending BridgeBio Pharma Inc (BBIO) as a Hold, while 9 are in view that stock is a Buy. Recommendation by 0 analysts for the stock is an Underweight while number of those analysts who rated the stock as an Overweight is 0, whereas 0 of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company.
Digging deeper we become aware of the PEG ratio of the BBIO stock which is currently positioned at 0. It further provides that stock’s current price level is 12.31% away from its 20-day simple moving average and is 22.03% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 77.59 while volatility remained at 3.87% over the past week which changes to 4.13% when measuring it over the past month. Beta is valued at 1.15. In predicting price targets of as low as $72 and as high as $72, analysts are in agreement on assigning the stock over the next 12 months average price target of $72. Stock’s current price level is -59.47% above from estimated low price target while it is -59.47% below the estimated high; and even if the BBIO’s share succeeded to reach the median price of $72, then the outlook of -59.47% could come to the excitement of the investors.
Having a second look at BridgeBio Pharma Inc (NASDAQ:BBIO) provides that stock’s average daily trading volume for 3 months was 2.97 million, while it jumped to 3189220 when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 189.83 million.
The percentage of outstanding shares held by the insiders is 15.35% while it is 85.70% for the institutional holders. The figures also indicate that as of 2025-06-13, number of stock’s short shares was 21.12 million which implies a short ratio of 8.11. This shows down a 1875.00 of Short Interest in company’s outstanding shares on the day. In June the standing of shares short improved as it was 22.4 million in the previous month. Addition of 93.11% by stock’s current price to its year-to-date value in today’s trading is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.
